Nordic Life Science 1
D ENMARK The Novo Nordisk Foundation Center for S
tem Cell Medicine reNEW, will be established based on a new consortium of three institutions. T HE FOUNDING OF the center is possible through a grant of up to 300 million EUR from the Novo Nordisk Foundation over a 10-year period. The center will be a collaboration between the University of Copenhagen, Denmark, Murdoch Children’s Research Institute, Australia, and Leiden University Medical Center, The Netherlands. The partnership between these three worldleading research institutions will pave the way for future stem cell-based treatments. Scientists at the three institutions will work in collaborative groups across all themes to provide new therapeutic options for patients with incurable diseases. Exchange programs and joint technology platforms in the reNEW model will fuel these collaborations and also the training of new generations of scientists in translational stem medicine. Professor Melissa Little from the Murdoch Children’s Research Institute, Australia, has been appointed as CEO of the reNEW partnership. The research activities within the Novo Nordisk Foundation Center for Stem Cell Medicine began in January 2022.